Rockefeller Capital Management
DSGN icon

Rockefeller Capital Management’s Design Therapeutics DSGN Stock Holding History

Rockefeller Capital Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53.3K Hold
3,684
– – ﹤0.01% 3343
2026
Q1 		$39.2K Buy
3,684
+2,946
+399% +$29.8K ﹤0.01% 3405
2025
Q4 		$6.92K Buy
+738
New +$5.78K ﹤0.01% 3954
2023
Q1 		– Sell
-61
Closed – – 2472
2022
Q4 		$0 Hold
61
– – ﹤0.01% 3920
2022
Q3 		$1K Hold
61
– – ﹤0.01% 3697
2022
Q2 		$0 Buy
+61
New +$824 ﹤0.01% 4162

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Rockefeller Capital Management's DSGN Position: Q2 2026 in Review

Rockefeller Capital Management held its Design Therapeutics (DSGN) position steady in Q2 2026 at 3,684 shares worth $53.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3343.

Rockefeller Capital Management first reported a position in DSGN in Q2 2022 and has held it in 6 quarters since. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Rockefeller Capital Management held 3,684 shares of Design Therapeutics worth $53.3K as of Q2 2026.
  • Rockefeller Capital Management left its Design Therapeutics share count unchanged in Q2 2026.
  • Design Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #3343 holding.
  • Rockefeller Capital Management first reported a position in Design Therapeutics in Q2 2022 and has held it in 6 quarters since.
  • 136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.